Janney Montgomery Scott LLC Increases Position in Tempus AI, Inc. $TEM

Janney Montgomery Scott LLC raised its stake in Tempus AI, Inc. (NASDAQ:TEM) by 256.2% during the 1st quarter, HoldingsChannel reports. The firm owned 65,043 shares of the company’s stock after acquiring an additional 46,782 shares during the period. Janney Montgomery Scott LLC’s holdings in Tempus AI were worth $2,941,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of TEM. JPL Wealth Management LLC purchased a new position in Tempus AI in the 3rd quarter valued at $26,000. Los Angeles Capital Management LLC purchased a new position in Tempus AI during the 4th quarter worth $27,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI during the 3rd quarter worth $38,000. Lodestone Wealth Management LLC acquired a new stake in shares of Tempus AI in the 4th quarter worth $42,000. Finally, CoreCap Advisors LLC lifted its stake in shares of Tempus AI by 135.1% in the 4th quarter. CoreCap Advisors LLC now owns 743 shares of the company’s stock worth $44,000 after acquiring an additional 427 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Price Performance

NASDAQ:TEM opened at $60.09 on Wednesday. The firm has a market cap of $10.79 billion, a price-to-earnings ratio of -34.94 and a beta of 3.46. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The company’s 50-day moving average is $50.82 and its two-hundred day moving average is $54.38. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.24) earnings per share. Research analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current year.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CFO James William Rogers sold 11,529 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $634,095.00. Following the completion of the transaction, the chief financial officer owned 114,866 shares in the company, valued at $6,317,630. This represents a 9.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 13,550 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $597,148.50. Following the sale, the chief executive officer directly owned 603,558 shares of the company’s stock, valued at approximately $26,598,801.06. The trade was a 2.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 572,759 shares of company stock worth $29,238,424. Company insiders own 24.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Guggenheim dropped their target price on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Jefferies Financial Group began coverage on Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target for the company. TD Cowen lifted their price target on Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and set a $80.00 price objective on shares of Tempus AI in a report on Monday, June 1st. Finally, Freedom Capital upgraded Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Nine analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $68.54.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.